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Abstract 
OBJECTIVE: To design and evaluate new pharmacogenomic (PGx) clinical decision support 
(CDS) alerts, built to adhere to PGx CDS design principles developed through socio-technical 
approaches. 
MATERIALS AND METHODS: Based on previously identified design principles, we created 
11 new PGx CDS alert designs and developed an interactive web application containing realistic 
clinical scenarios and user workflows that mimicked a real-world EHR system.  We recruited 
General Internal Medicine and Cardiology clinicians from Northwestern Medicine and recorded 
their interactions with the original and new designs.  We measured clinician response, 
satisfaction, speed, and confidence through questionnaires and analysis of the recordings. 
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RESULTS: The study included 12 clinicians.  Participants were significantly more satisfied 
(p=0.0000001), faster (p=0.009), and more confident (p<.05) with the new designs than the 
original ones.  The study lacked statistical power to determine whether prescribing accuracy was 
improved, but participants were no less accurate, and clinical actions were more concordant with 
alert interactions (p=0.004) with the new designs.  We found a significant learning curve 
associated with the original designs, which was eliminated with the new designs. 
DISCUSSION: This study successfully demonstrates that socio-technical and user-centered 
design techniques can improve PGx CDS alert designs.  Best practices for PGx CDS design are 
limited in the literature, with few effectiveness studies available.  These results can help guide 
future PGx CDS implementations to be more clinician friendly and less time-consuming. 
CONCLUSION: The results of this study support the PGx CDS design principles we proposed in 
previous work.  As a next step, the new designs should be implemented in a live setting for 
further validation. 
 
Background and Significance 
 Traditional approaches to drug prescribing have inefficiencies that create a substantial 
burden on the U.S. healthcare system.  Some patients experience expensive and life-altering 
adverse drug events and adverse drug reactions, while others experience a lengthy trial-and-error 
process to find therapeutic drugs and dosages.[1] Precision medicine has the potential to mitigate 
these issues by tailoring drug prescribing more accurately for the individual patient.[2] 
Pharmacogenomics (PGx) has shown promise as a route for meaningful implementation of 
precision medicine in a variety of clinical scenarios.[3-7]  However, clinicians are not currently 
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well educated on the benefits of PGx, or on methods to implement it effectively in treating 
patients.[8,9] Additionally, the rapidly changing field of genomics makes it hard for any one 
individual to keep up with the shifting science and associated clinical recommendations.  Clinical 
decision support (CDS) systems have the ability to close this gap by conveying useful PGx 
knowledge to prescribers at the point of care,[10] without requiring time-consuming continuing 
medical education that most clinicians find burdensome.[11] 
 To-date, PGx CDS systems have shown mixed results in their level of effectiveness and 
clinician-acceptance.  The wide variation in the design and outcomes of first-generation PGx 
CDS systems confirms that there are no current, widely accepted best practices for how to design 
alerts to be as effective and useful for clinicians as possible.  We previously examined the alerts 
implemented at Northwestern Medicine (NM) and found generally low acceptance and 
compliance rates with PGx recommendations.[12] Other sites in the Electronic Medical Records 
and Genomics (eMERGE) Network showed a wide range of effectiveness and design choices, 
though with some emerging consensus around the use of post-genetic test, interruptive alerts 
based on Clinical Pharmacogenetics Implementation Consortium (CPIC) recommendations 
integrated into the EHR.[13] Non-eMERGE sites have taken a variety of different approaches to 
their implementations, as well.  The Genomic Prescribing System at the University of Chicago is 
a standalone system that has been shown to affect prescriber decision-making using “traffic 
light” recommendations,[14,15] while St. Jude’s and the NIH Clinical Center developed 
interruptive alerts, with substantially different clinician compliance rates.[16,17] 
Although a number of sites have opted for interruptive alerts, there remains wide 
variation in the design and function of those alerts. For PGx CDS to reach its potential, we must 
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establish best practices and guidelines for alert design to ensure that knowledge is conveyed to 
prescribers in a meaningful way that will actually improve patient care and outcomes.  Non-PGx 
CDS has a broad base of research to draw upon,[18-21] but low levels of provider education in 
PGx raises the possibility that information needs for PGx CDS may be substantially different 
from areas where clinicians have been extensively trained, such as drug-drug and drug-allergy 
interactions. 
Socio-technical design methods have the potential to help identify clinician needs and 
best practices for PGx CDS.  These methods emphasize inclusion of the user in the design 
process in order to best evaluate actual needs.  They also utilize repeated evaluation of, and 
iteration upon, designs.[22-24] In prior work, we applied these techniques and identified several 
potential principles for PGx CDS alert design.[25] In this study, we build upon that work and 
propose and evaluate a series of updated PGx CDS designs based on those principles, in 
comparison to the previous committee-developed designs at NM.  We suggest that the designs 
based on socio-technically developed principles will lead to better response by clinicians on a 
variety of metrics.  If effective, then these principles can be adopted more broadly in the field to 
ensure PGx CDS reaches its potential for bringing precision medicine to fruition. 
 
Objective 
This study sought to compare clinician response to PGx CDS (including action taken, 
time taken, confidence, and overall satisfaction) for alert designs built with two different 
approaches.  The first approach was a set of committee-developed designs, established through 
informal user input and previously implemented at Northwestern Medicine.  The second 
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approach was a set of revised designs, based on the results of formal socio-technical design work 
described in a previous paper.[25] 
 
Materials and Methods 
Overview 
 Participants in this study took part in a user test consisting of a series of 24 interactive 
simulations based on fictionalized, but realistic, clinical scenarios involving PGx CDS and were 
asked to engage in a think-aloud protocol.  Simulations were designed to mimic familiar EHR 
workflows.  Twelve scenarios used existing PGx CDS alert designs, developed in earlier phases 
of NU’s eMERGE-PGx project (“original designs”).  Twelve scenarios used new PGx CDS alert 
designs, developed via socio-technical design methods (“new designs”).  After each scenario, 
participants were asked to rate their confidence in their actions and explain their reasoning if 
they chose to ignore an alert.  After completing all 24 scenarios, participants completed a short 
questionnaire assessing their preferences between the different designs.  All testing sessions 
included screen and audio recording for later analysis.  The Northwestern IRB approved all 
aspects of this study. 
 
Study Development 
Alert Development 
 We first developed a series of new PGx CDS design prototypes.  These designs were 
based on the results of prior research and on general human-computer interaction and user 
interface design principles applicable to clinical decision support.[18-21,25] New design 
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prototypes were initially developed by TMH and then iteratively refined based on group 
feedback (JBS, LVR, TAM).  The design principles established from prior research, and how 
they were addressed in the new designs, are detailed in Table 1.  Some of these principles and 
approaches are consistent with those used in traditional CDS, but several are unique to PGx 
CDS, including the use of stronger wording in recommendations, the use of phenotypes 
abstracted from the underlying genotype data, and emphasis on adaptability for learning effects.  
Figure 1 provides an example comparing an original design to a new design. 
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Table 1 – Pharmacogenomic Clinical Decision Support Design Principles Used 
Design Principle[a] Addressed By… 
Be Specific and 
Actionable 
• A large, bold, colored banner stating exactly what the alert is for 
(e.g., “MEDICATION CHANGE RECOMMENDED”) 
• An exact recommended alternative medication and dose instead 
of a list of “alternatives to consider” 
• Accepting an alert or requesting educational materials 
automatically updates the user’s order without additional clicks 
• Desired additional actions are clearly laid out with buttons to 
confirm their completion 
Be Brief • Longer verbiage is de-emphasized in favor of color-coded 
medication names that make it clear what is recommended and 
what is not 
• Educational materials are available by a link and longer 
justifications are placed lower in the alert 
Display 
Phenotypes not 
Genotypes 
• Instead of genetic results like “CYP2C19 *2/*2,” alerts contain 
phenotypes like “Clopidogrel Poor Metabolizer” 
• All genetic results are available via links to laboratory results for 
those who are interested 
Rely on Sources 
Clinicians Already 
Trust 
• Alerts mention Northwestern Medicine or the Northwestern 
Pharmacy & Therapeutics committee 
Be Adaptable to 
Learning Effects 
• Some alerts appear in summary form that can be expanded for 
more details 
• All alerts are designed to be easily skimmed by those with more 
experience, with details and links for those that need more 
information 
[a] Design principles derived from previous work.[25] 
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Figure 1 – PGx CDS Design Comparison 
Original Design: 
 
 
New Design, Brief: 
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New Design, Expanded: 
 
 The new alerts were developed for the same drug-gene interactions (DGIs) and clinical 
scenarios as in previous eMERGE-PGx work, but with updated UIs and workflows.  Table 2 
details each of the eleven distinct alerts that were developed. 
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Table 2 – Pharmacogenomic Clinical Decision Support Alerts Developed 
Drug Active/Passive Predicted Phenotype Medication Status 
Clopidogrel Active Intermediate Metabolizer Actively Prescribing 
Poor Metabolizer Actively Prescribing 
Passive Intermediate Metabolizer Not on Medication 
Intermediate Metabolizer On Medication 
Poor Metabolizer Not on Medication 
Poor Metabolizer On Medication 
Simvastatin Active Intermediate Activity Actively Prescribing 
Low Activity Actively Prescribing 
Passive Intermediate Activity Not on Medication 
Low Activity On Medication 
Warfarin Active Sensitive Actively Prescribing 
 
 Active alerts are defined as interruptive alerts that appear when a clinician chooses one of 
the affected drugs during order entry and the patient has a relevant genetic result on file.  Passive 
alerts are defined as non-interruptive alerts that appear in the “Best Practice Advisories” tab of 
the patient’s EHR chart when the patient has a relevant genetic test result on file.  Passive alerts 
are optional to view and respond to.  In this study, Active alerts were used only for medication 
change recommendations during order entry, while Passive alerts were used for either 
medication change recommendations when the patient is currently on a relevant medication, or 
for educational purposes when the patient is not currently on a relevant medication. 
Scenario Development 
 A total of 24 different clinical scenarios were developed, using fictional patient 
information.  Each scenario was based on common clinical indications for use of clopidogrel, 
simvastatin, and warfarin.  One scenario was developed for each of the eleven new alert designs, 
with an additional scenario for warfarin.  The additional scenario for warfarin would allow 
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participants multiple exposures to warfarin alerts under different clinical conditions.  This 
resulted in a total of twelve unique scenarios.  Analogous scenarios were then developed and 
paired with the original designs, resulting in a total of 24 testing scenarios.  Patient demographics 
and scenario wording were altered slightly to avoid clear repetition and immediate recognition 
by participants. 
The fictitious patient information for each scenario was based on typical patient 
demographics for users of these particular medications.  Scenarios were evenly split between 
male and female.  Height, weight, and smoking status were based on national averages.  Ages 
were chosen to be clinically reasonable according to national averages for the clinical indication 
and medication relevant to that scenario. 
In addition to patient demographics, each scenario had an associated initial medication 
(clopidogrel/simvastatin/warfarin), a recommended alternative (prasugrel/atorvastatin/reduced 
warfarin dose), and an expected action (accept alert/dismiss alert). 
 All scenarios (including the expected action) were independently reviewed for clinical 
validity by two MDs before being presented to participants (JBS and one non-author).  
Reviewers concurred and neither recommended any changes to the scenarios, as written. 
Simulation Development 
 Interactive simulations were developed as a web application, using HTML, JavaScript, 
and CSS.  The user interface was created in an image manipulation program and was based on a 
series of screenshots from NM’s actual EHR implementation (Epic Systems Corporation, 
Verona, WI).  All simulated alerts were interactive, with functional hyperlinks, educational 
materials, and buttons.  However, most workflow aspects outside of the alerts were removed or 
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abbreviated for simplicity.  In particular, for scenarios using the original designs, the workflow 
for ordering after-visit summary materials and for updating a medication were greatly shortened.  
Figure 2 shows an example of a simulated workflow using one of the new alert designs. 
 Figure 2 – Example Simulation 
Screenshot of a simulated EHR sequence in a web application built for user testing of new pharmacogenomic clinical decision support 
alert designs.  Here, the user has attempted to order 75mg of clopidogrel when the patient is a poor metabolizer. 
 
1
3
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Study Execution 
 Study participants were recruited from NM’s General Internal Medicine (GIM) and 
Cardiology departments.  Participants were approached via e-mail, based on their participation in 
previous eMERGE studies or through snowball sampling through referrals from other 
participants.  All participants were compensated with a $100 gift card for their participation. 
 All testing sessions were conducted via think-aloud protocol, either in person or via 
virtual conference, with the first author present.  Participants were encouraged to share their 
thought processes while executing each of the simulations in order to benefit later review and 
analysis.  Participants were permitted to ask questions about the simulations as they went 
through their testing session.  All sessions were recorded via a virtual conferencing application 
and were later exported to standalone video.  In-person participants were provided a mouse and 
laptop with the testing application pre-loaded and configured.  Virtual conference participants 
used their own PCs and were provided a copy of the web application ahead of time to run 
locally. 
 To mitigate potential learning effects, participants were evenly divided into “Original 
First” and “New First” conditions.  The scenarios and associated simulations were identical for 
all participants, but the simulation order varied, as follows: The Original First group saw the 
twelve original designs first, followed by the twelve new designs.  The New First group saw the 
twelve new designs first, followed by the twelve original designs.  The order of the scenarios 
within each “bundle” was randomized for each participant.  There was no “washout period” 
between the bundles of scenarios, as the participants proceeded immediately from the first group 
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to the second group.  Participants were assigned to their respective groups on an alternating 
basis. 
 The overall study flow was identical for each participant, outside of the simulation order.  
Each session started with the participant consenting to the study, followed by five verbal 
demographics questions assessing their experience, education, and familiarity and comfort with 
PGx.  Participants were then provided with the web application for user testing.  The web 
application began with an instruction screen, from which participants clicked a link to begin the 
study.  Participants then saw a Scenario Description screen with a short paragraph detailing the 
clinical scenario and a link to begin the simulation.  They would then execute the simulation and 
complete it by clicking a “Sign Visit” or “Sign Orders” button.  This was followed by a short 
screen asking them to rate their confidence in their choice on a 0-10 Likert scale and, if they 
ignored or dismissed an alert, asking them to verbally explain their rationale to the interviewer.  
Participants would then click a link to view the next Scenario Description screen and repeated 
this process for all 24 simulations.  After the final post-simulation screen, participants were taken 
to a wrap-up questionnaire where they answered five Likert-scale questions to assess their 
preferences between the original and new designs, and three open-ended questions to determine 
any recommendations they may have for further improving the alert designs.  All questions 
asked for opinions on “Type 1” or “Type 2” alerts.  Type 1 and Type 2 were alternated for each 
participant, depending on whether they saw the original designs or new designs first. 
 
Analysis 
Analysis was divided into four key metrics: Response, Satisfaction, Speed, and 
Confidence, each with a different means of assessment. 
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In concordance with prior work by this research group,[12,13] Response was defined in 
two ways: Alert Response and Clinical Response.  Alert Response was the response to the alert 
itself in the simulated EHR and could be either Accept (i.e., the user clicked the “Accept” button 
on the alert) or Ignore (i.e., the user clicked the “Dismiss” button on the alert or proceeded with 
no interaction on the alert).  Clinical Response was the clinical action taken and could be either 
Followed (i.e., the user ordered the recommended alternative medication) or Not Followed (i.e., 
the user did not order the recommended alternative medication).  The expected and actual 
responses were were compared for both the Alert Response and Clinical Response.  Each 
participant viewed many simulations, so each individual action is not independent.  Therefore, 
we assigned individuals to a High Compliance or Low Compliance category for analysis via 
McNemar’s test.  Participants were assigned to the Low Compliance category if they performed 
the expected action less than 80% of the time and to the High Compliance category if they 
performed the expected action at least 80% of the time.  Discordance between Alert Response 
and Clinical Response (i.e., prescribing actions that do not match the action a clinician took on 
an alert for a particular scenario) was similarly tested. 
Satisfaction was measured based on five Likert-scale questions asked at the end of each 
testing session.  Additionally, the mean of the five satisfaction scores was calculated to derive a 
single Overall Satisfaction score.  For analysis, all satisfaction scales were normalized to refer to 
“original design” and “new design” alerts instead of “Type 1” and “Type 2.”  Likert-scales were 
a five-point scale that ranged from “Significantly prefer original design” to “Significantly prefer 
new design” and were assigned values from -2 to +2, with Neutral being 0. 
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Speed was determined by the number seconds elapsed from the time the participant 
clicked the “Begin Simulation” link for each scenario to the time they clicked the “Sign Visit” or 
“Sign Orders” button to complete the scenario.  This value was determined through a frame-by-
frame examination of the session recordings by the first author. 
Confidence was determined by a combination of the individual “0-10” confidence scores 
participants provided at the end of each scenario, as well as an overall confidence question asked 
during the wrap-up questionnaire phase. 
 
Results 
Basic Demographics 
 Twelve clinicians agreed to take part in this study, including eleven MDs and one PA.  
Six participants were board certified in internal medicine only and six were board certified in 
cardiology-related specialties.  Participants had an average of 18 years of experience and spent 
13.5 hours per week seeing patients.  When asked about their comfort with genetics and 
pharmacogenetics, four participants expressed low comfort levels, six expressed fair or moderate 
comfort levels, and two expressed high comfort levels.  Participants generally reported 
infrequent use of genetic data in their practice, with only one participant saying they used genetic 
data often.  This is consistent with responses seen in previous publications.[12,13] 
A technical issue compromised the measurements for one participant during the study.  
This participant viewed five of the new alert designs and nine of the original designs, instead of 
twelve of each.  This participant’s results are excluded in the individual response and time-based 
analyses but are included for the overall attitude-based analyses.  One participant skipped a 
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single scenario in the study due to a technical error and viewed only eleven of the twelve original 
designs. This participant’s results are fully included in all analyses. 
Response 
 For the Alert Response metric, there was little evidence that the new alert designs 
affected clinicians’ choices to Accept or Ignore alerts.  There was no detectable difference in 
compliance rates between the original designs and new designs. Of the 131 scenarios where 
participants saw the original design, they performed the expected Accept or Ignore action 91 
times (69.5%).  Of the 132 scenarios where participants saw the new alert design, they performed 
the expected action 96 times (72.7%).  For statistical analysis, participants were labeled as High 
Compliance if they performed the expected action at least 80% of the time.  Compliance statuses 
are reported in Table 3.  The compliance rates with the original and new designs were identical. 
(McNemar’s Test; H0: pb=pc; p=1) 
Table 3 – Alert Response Compliance Rates (# of Participants) 
 
Original Design 
High Compliance Low Compliance Total 
New 
Design 
High Compliance 3 2 5 
Low Compliance 2 4 6 
Total 5 6 11 
 
 For the Clinical Response metric, there was a trend towards better adherence to alert 
recommendations, but this study lacked the power to demonstrate a statistically significant 
difference.  Of the 109 scenarios where participants saw the original design and were expected to 
order a medication, they ordered the expected medication 72 times (66.1%).  Of the 110 
scenarios where participants saw the new alert design and were expected to order a medication, 
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they ordered the expected medication 84 times (76.4%).  Again, participants were labeled as 
High Compliance if they performed the expected action at least 80% of the time.  Compliance 
statuses are reported in Table 4.  Despite lacking statistical power to demonstrate significant 
difference, compliance rates trended towards improved compliance rates with the new designs. 
(McNemar’s Test; H0: pb=pc; p=0.13) Alternative thresholds for the compliance labels did not 
alter this conclusion. 
Table 4 – Clinical Response Compliance Rates (# of Participants) 
 
Original Design 
High Compliance Low Compliance Total 
New 
Design 
High Compliance 3 4 7 
Low Compliance 0 4 4 
Total 3 8 11 
 
 Discordance between Alert Response and Clinical Response was present with the original 
designs (i.e., clinicians did not always perform a clinical action that matches their response to an 
alert) but eliminated with the new designs.  Of the 109 scenarios where participants saw the 
original design and were expected to order a medication, they performed discordant actions 27 
times (24.8%).  Of the 110 scenarios where participants saw the new alert design and were 
expected to order a medication, they performed discordant actions 0 times (0%).  Discordance 
rates are reported in Table 5.  Discordance between Alert Response and Clinical Response was 
eliminated with the new designs. (McNemar’s Test; H0: pb=pc; p=0.004) 
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Table 5 – Alert Response vs. Clinical Response Discordance Rates 
 
Original Design 
0% Discordance >0% Discordance Total 
New 
Design 
0% Discordance 1 10 11 
>0% Discordance 0 0 0 
Total 1 10 11 
 
Satisfaction 
 Participants showed a strong preference for the new alert designs.  On the -2 to +2 scale 
(significantly prefer original designs to significantly prefer new designs), the mean Overall 
Satisfaction score was 1.37 (one sample, one-tailed t-test; H0: µ=0; p=0.0000001).  Overall 
Satisfaction does not appear to be affected by the New First or Original First condition into 
which the participant was placed.  Those in the Original First condition had an average Overall 
Satisfaction score of 1.30, while those in the New First condition had an average Overall 
Satisfaction score of 1.43.  This difference was not statistically significant (two sample t-test; H0: 
µ1=µ2; p=0.61). 
 Responses to the individual satisfaction questions leaned heavily towards a preference for 
the new designs.  Only one participant, on one question, preferred the original designs to the new 
designs.  All other responses expressed preference for the new designs or were neutral.  Figure 3 
shows how each participant answered each of the five questions and Figure 4 shows the 
preference distributions for each question.  All five individual questions showed preference for 
the new designs, via one-sample Wilcoxon Signed Rank analysis, both without and with 
Bonferroni correction for multiple tests.  Results on the individual questions are summarized in 
Table 6.
 Figure 3 – PGx CDS Version Preferences 
Preferences expressed by twelve participants comparing Original and New pharmacogenomic clinical decision support alert designs. 
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Figure 4 – Reported Preferences for Original Designs vs. New Designs 
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Speed 
Participants completed tasks significantly faster with the new alert designs than with the 
original alert designs.  The average time taken to complete a single simulation was 61 seconds 
(SE: 7.7) with the original designs and 40 seconds (SE: 4.3) with the new designs, for a 
difference of 21 seconds (paired two sample for means, one-tail t-test; H0: µ1≤µ2; p=0.009; 99% 
CI: 0.5<µ2-µ1<42.4). 
 
Learning Curve 
Most of the difference in task time comes from the earliest tasks in each sequence, 
indicating a likely learning curve for the original designs.  Participants who saw the original 
designs first were much slower at earlier simulations than they were at later ones.  Conversely, 
participants who saw the new alert designs first showed similar task times from start to finish.  
Figures 5 and 6 show the task times for each participant, separated by the Original First and New 
First conditions. 
 Figure 5 – Task Times (Original First) 
Simulation task times for each participant who saw Original designs for tasks 1-12 and New designs for tasks 13-24. Results show a 
decrease in average task time as the simulations progress. (Time: m:ss) 
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Figure 6 – Task Times (New First) 
 
Simulation task times for each participant who saw New designs for tasks 1-12 and Original designs for tasks 13-24. Results show a 
consistent task time as the simulations progress. (Time: m:ss) 
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 Because of the randomized nature of the simulation order, direct one-to-one comparisons 
for each task was not feasible.  So, to evaluate the possible learning curve, we examined the 
mean task times in three separate buckets: First Four, Second Four, and Third Four.  Table 6 
shows that there is a significant time difference in the first four tasks for the Original First group 
over the New First group.  The difference in mean times for the Second Four and Third Four 
buckets is much smaller and not statistically significant.  Furthermore, there was no difference in 
average task time between the original designs and new designs when seen second, at 42 and 39 
seconds, respectively (two sample, one-tail t-test; H0: µ1≤µ2; p=0.34).  Taken all together, this is 
evidence that the time differences are due to a substantial learning curve with the original 
designs that is not present with the new designs, and that the learning curve exists within the first 
four exposures. 
Table 6 – Grouped Averages, Mean Time Difference, Original First vs. New First 
Scenarios 
Original First 
(M:SS) 
New First 
(M:SS) 
Difference 
(M:SS) 
P-value 
(one-tailed t-test) 
Bonferroni 
Corrected 
First 4 1:58 0:41 1:17 0.00556274 0.016688219 
Second 4 1:04 0:50 0:14 0.273955594 0.821866781 
Third 4 0:49 0:30 0:19 0.068835658 0.206506973 
 
Confidence 
 Participants reported a small but statistically significant increase in confidence levels 
with the new alert designs.  They reported an average confidence score of 7.81 when acting on 
an alert with an original design, compared to 8.16 when acting on an alert with a new design, for 
an increase of 0.35 (Paired two sample for means, one-tail, t-test; H0: µ1≤µ2; p<.05). 
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Discussion 
 This study successfully demonstrates that socio-technical techniques can improve PGx 
CDS alert designs.  Participants in this study showed greater satisfaction, lower task times, 
greater confidence, and improved concordance of actions when interacting with revised alerts, 
with no evidence of any deleterious effects on accuracy. 
Though we were unable to demonstrate that the new designs lead to greater accuracy, we 
did find a positive trend in Clinical Response that may be significant with greater statistical 
power.  Additionally, clinician behavior was more concordant between Alert Response and 
Clinical Response.  This is likely due to a workflow change in the new designs.  The new designs 
automatically update the user’s order with the recommended medication when they accept an 
alert (a reflection of the “Be Specific and Actionable” design principle), while the original 
designs require users to manually update their order.  This manual process introduces the 
opportunity for divergence between the Alert Response and Clinical Response actions, which 
could cause confusion for users and complications for system evaluators. 
The increase in confidence we observed from individual scenario scores is further 
supported by the results from the end-of-study questionnaire, where participants reported being 
more confident overall with the new designs.  However, that result was the weakest of the five 
end-of-study questions, which aligns with the relatively modest increase in confidence that we 
found. 
 The Alert Response and Clinical Response rates in this study were significantly higher 
than rates found in live clinical data in a previous study at NM, where clinicians accepted the 
original-style alerts 42.5% of the time and ordered an alternative medication 22.5% of the 
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time.[12] These rates are substantially lower than in this study, where clinicians accepted the 
original designs 69.5% of the time and ordered an alternative medication 66.1% of the time.  
There are several possible reasons for this result, including that the simulations in this study were 
not time-bound, so participants were able to take the time they needed to review alerts and make 
a choice in which they felt confident.  In live clinical settings, users may be reluctant to take the 
time to review the unfamiliar alerts and change their behavior, particularly given the substantial 
learning curve we found for the original designs.  We do not see any reason to believe this would 
bias one condition over the other in our study.  Also, given the reduced learning curve and task 
times with the new designs, clinicians may be even more likely to follow the new designs in a 
time-constrained setting, leaving our overall conclusions unchanged.   Additionally, the 
Hawthorne Effect[26] may be present in this study, as participants were fully aware that they 
were being observed.  But again, we see no reason to believe this would bias one condition over 
the other, and therefore do not believe our conclusions are affected. 
 The present study adds to a small but growing base of literature examining the 
effectiveness of PGx CDS, of which some previous studies have also utilized socio-technical 
approaches.  Our results dovetail with previous studies from the University of Washington. 
Devine, et al. found that physicians expressed a desire for PGx CDS to “provide succinct, 
relevant guidelines and dosing recommendations of phenotypic information from credible and 
trustworthy sources; any more information was overwhelming.”[27] Here, we find that such 
designs do, in fact, improve physician satisfaction with PGx CDS.  Subsequently, Overby et al. 
performed an evaluation of a PGx CDS prototype and found that PGx CDS lowered physician 
confidence in their decision-making, but significantly altered their dosing decisions.[28] Our 
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results contradict those findings, as we found an increase in confidence but little change in 
decision making.  It is likely that differences in design, workflow, or physician characteristics 
contributed to these divergent results, which emphasizes the need for further research to fully 
understand how such factors affect clinician response to PGx CDS.  Our findings are congruent 
with their conclusion that effective PGx CDS is “likely to be realized through continued focus on 
content, content delivery, and tailoring to physician characteristics.”[28] 
 Other reports of PGx CDS effectiveness include a study by O’Donnell, et al. that found 
PGx CDS was effective in altering prescriber behavior.[14] Their Genomic Prescribing System 
differs dramatically from the designs at NM, relying on a standalone web application using 
“traffic light” style alerts to provide recommendations, as opposed to interruptive alerts 
integrated into the EHR.  Similarly, Bell, et al. found 95% compliance rates with PGx CDS in 
treating pediatric lymphoma and leukemia patients.[16] Conversely, St. Sauver, et al. found only 
30% compliance with PGx CDS, and that “clinicians felt that the alerts were confusing, 
irritating, frustrating, or that it was difficult to find additional information.”[29] Results from an 
eMERGE-wide pilot study of clinician response to PGx CDS were heavily mixed, with alert 
adherence rates ranging from 21% to 73%, depending on the site.[13] Melton, et al. found that 
incorporating user feedback during development of warfarin-based CDS increased acceptance of 
recommendations, but did not alter overall satisfaction with system prototypes.[30] The present 
study fits the broader body of literature in that it underscores the lack of consensus around 
optimal PGx CDS design and clinician response, and provides promising direction for those that 
wish to avoid designs that would frustrate or irritate users. 
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This study does not seek to evaluate the appropriateness and value of PGx CDS in 
general, nor does it seek to recommend particular clinical scenarios where PGx CDS may be 
most beneficial.  Instead, this study focuses exclusively on improving alert designs so that they 
may be more effective in any particular scenario where an individual healthcare organization has 
deemed PGx CDS necessary and/or beneficial. 
The simulated nature of the study does not perfectly mimic an actual clinical setting with 
all the time pressures, potential distractions, and emotional involvement of an actual patient that 
such a setting would entail.  We instructed clinicians to work quickly and act as they would with 
a real patient, but the extent to which they were able to accomplish this is unclear. 
The times collected for the speed metric are not likely to reflect actual clinical times 
because of the think-aloud protocol the study employed.  However, there is little reason to 
believe that the time required to think aloud would change the conclusion that the new designs 
are faster for clinicians.  Several articles in the literature discuss how think-aloud protocols affect 
task times and accuracy, but we were unable to find any case where such protocols would bias 
one study condition over another when both conditions include a think-aloud component.[31,32] 
Additionally, as described in the Materials and Methods section, the simulations for the original 
designs were significantly shortened to reduce complexity in the web application. The 
simulations for the new designs were not shortened, a fact that further strengthens our 
conclusions.  Moreover, most of the time difference was due to a large learning curve with the 
original designs, where early exposures took clinicians much longer to respond.  Given the low 
frequency of interaction that clinicians have with PGx CDS in real-world clinical settings,[12] 
we expect that the earlier, slower times in this study more closely reflect real-world interactions.  
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With these limitations in mind, we conclude that the new designs are faster, with a reduced 
learning curve, but we make no claim as to the magnitude of the change in real-world task time. 
This study is further limited by its sampling methods.  Participants were not randomly 
sampled, but instead were clinicians that had worked with PGx before, had participated in a prior 
eMERGE-PGx study, or who showed interest in the project via professional networking.  
Furthermore, participation was limited to GIM and Cardiology departments at a single large, 
academic medical center.  All of these factors make it possible that participants were more 
informed about PGx in general, and as such, the results may not generalize to other clinical 
populations.  However, the low to moderate comfort level with, and infrequent use of, genetics 
that participants reported may indeed reflect the attitudes of a typical clinician. 
Future work can build upon this study in a number of ways.  We recorded the user testing 
sessions and asked participants to think aloud during their simulations, which could provide 
additional fruitful data.  The final wrap-up survey also asked open-ended questions that 
encouraged participants to suggest improvements to the new designs.  These qualitative analyses 
are left for a future study.  Anecdotally, there are minor tweaks that could lead to even greater 
satisfaction with the new designs – such as a “Preview” link for the patient educational materials 
and renaming the “Accept” button to “Order [alternative]” to further clarify the workflow. 
Most importantly, this successful pilot demonstration should be followed up with a real-
world implementation and evaluation.  To the extent that it is technically feasible, the alert 
designs in this study should be translated to live alerts in an active EHR and subjected to similar 
evaluations as our previous studies of the original alert designs.[12] Iteration and continual 
improvement are critical aspects of socio-technical design. 
32 
 
Conclusion 
This study validates the PGx CDS design principles we previously proposed and provides 
strong evidence that socio-technical design approaches lead to better results with PGx CDS than 
design by committee.  The updated designs tested in this study led to more satisfied, faster, and 
more confident clinicians who were at least as accurate in their decision making as with prior, 
committee-developed designs.  These results support previous findings that, for PGx, clinicians 
prefer brief, actionable alerts that contain specific recommendations based on interpreted 
phenotypes.  As a next step, these alert designs should be implemented in a live clinical setting to 
confirm that they lead to similar real-world results. 
 
33 
 
REFERENCES 
 
1 Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. J 
Pharmacol Pharmacother 2013;4(Suppl 1):S73-7 
2 Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in 
reducing adverse drug reactions: a systematic review. Jama 2001;286(18):2270-9 
3 Gvozdic K, Brandl EJ, Taylor DL, Muller DJ. Genetics and personalized medicine in 
antidepressant treatment. Current pharmaceutical design 2012;18(36):5853-78 
4 Gelissen IC, McLachlan AJ. The pharmacogenomics of statins. Pharmacological research : the 
official journal of the Italian Pharmacological Society 2013 
5 Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation 
consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 
2013 update. Clin Pharmacol Ther 2013;93(4):324-5 
6 Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium 
guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol 
Ther 2013;94(3):317-23 
7 Weng L, Zhang L, Peng Y, Huang RS. Pharmacogenetics and pharmacogenomics: a bridge to 
individualized cancer therapy. Pharmacogenomics 2013;14(3):315-24 
8 Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians' knowledge of 
and experience with pharmacogenetic testing. Clin Genet 2012;82(4):388-94 
9 Stanek EJ, Sanders CL, Taber KA, et al. Adoption of pharmacogenomic testing by US 
physicians: results of a nationwide survey. Clin Pharmacol Ther 2012;91(3):450-8 
34 
 
10 Welch BM, Kawamoto K. Clinical decision support for genetically guided personalized 
medicine: a systematic review. J Am Med Inform Assoc 2013;20(2):388-400 
11 Cook DA, Blachman MJ, West CP, Wittich CM. Physician Attitudes About Maintenance of 
Certification: A Cross-Specialty National Survey. Mayo Clinic proceedings 
2016;91(10):1336-45 
12 Herr TM, Smith ME, Starren JB. A Mixed-Methods Analysis of Clinician Response and 
Adherence to Pharmacogenomic Clinical Decision Support: Northwestern University, 
2019. 
13 Herr TM, Peterson JF, Rasmussen LV, Caraballo PJ, Peissig PL, Starren JB. 
Pharmacogenomic clinical decision support design and multi-site process outcomes 
analysis in the eMERGE Network. J Am Med Inform Assoc 2019;26(2):143-48 
14 O'Donnell PH, Wadhwa N, Danahey K, et al. Pharmacogenomics-Based Point-of-Care 
Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther 
2017;102(5):859-69 
15 O'Donnell PH, Danahey K, Jacobs M, et al. Adoption of a clinical pharmacogenomics 
implementation program during outpatient care--initial results of the University of 
Chicago "1,200 Patients Project". Am J Med Genet C Semin Med Genet 
2014;166C(1):68-75 
16 Bell GC, Crews KR, Wilkinson MR, et al. Development and use of active clinical decision 
support for preemptive pharmacogenomics. J Am Med Inform Assoc 2014;21(e1):e93-9 
17 Goldspiel BR, Flegel WA, Dipatrizio G, et al. Integrating pharmacogenetic information and 
clinical decision support into the electronic health record. J Am Med Inform Assoc 2013 
35 
 
18 Bates DW, Kuperman GJ, Wang S, et al. Ten commandments for effective clinical decision 
support: making the practice of evidence-based medicine a reality. J Am Med Inform 
Assoc 2003;10(6):523-30 
19 Horsky J, Schiff GD, Johnston D, Mercincavage L, Bell D, Middleton B. Interface design 
principles for usable decision support: a targeted review of best practices for clinical 
prescribing interventions. J Biomed Inform 2012;45(6):1202-16 
20 Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical 
decision support systems: a systematic review of trials to identify features critical to 
success. BMJ 2005;330(7494):765 
21 Payne TH, Hines LE, Chan RC, et al. Recommendations to improve the usability of drug-
drug interaction clinical decision support alerts. J Am Med Inform Assoc 
2015;22(6):1243-50 
22 Baxter G, Sommerville I. Socio-technical systems: From design methods to systems 
engineering. Interact Comput 2011;23(1):4-17 
23 Coiera E. Putting the technical back into socio-technical systems research. Int J Med Inform 
2007;76 Suppl 1:S98-103 
24 The social-technical design circle. Proceedings of the 1996 ACM conference on Computer 
supported cooperative work; 1996. ACM. 
25 Herr TM, Nelson TA, Starren JB. Principles for Pharmacogenomic Clinical Decision Support 
Design Based on Clinician Preferences in an Academic Medical Center: Northwestern 
University, 2019. 
36 
 
26 McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new 
concepts are needed to study research participation effects. J Clin Epidemiol 
2014;67(3):267-77 
27 Devine EB, Lee CJ, Overby CL, et al. Usability evaluation of pharmacogenomics clinical 
decision support aids and clinical knowledge resources in a computerized provider order 
entry system: a mixed methods approach. Int J Med Inform 2014;83(7):473-83 
28 Overby CL, Devine EB, Abernethy N, McCune JS, Tarczy-Hornoch P. Making 
pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study 
with physicians. J Biomed Inform 2015;55:249-59 
29 St Sauver JL, Bielinski SJ, Olson JE, et al. Integrating Pharmacogenomics into Clinical 
Practice: Promise vs Reality. The American journal of medicine 2016;129(10):1093-99 
e1 
30 Melton BL, Zillich AJ, Saleem J, Russ AL, Tisdale JE, Overholser BR. Iterative Development 
and Evaluation of a Pharmacogenomic-Guided Clinical Decision Support System for 
Warfarin Dosing. Appl Clin Inform 2016;7(4):1088-106 
31 Wright RB, Converse SA. Method Bias and Concurrent Verbal Protocol in Software Usability 
Testing. Proceedings of the Human Factors Society, 36th Annual Meeting, Vols 1 and 2 
1992:1220-24 
32 Ransdell S. Generating Thinking-Aloud Protocols - Impact on the Narrative Writing of 
College-Students. Am J Psychol 1995;108(1):89-98 
 
